^
Association details:
| Biomarker: | TCF7 overexpression + CD8 overexpression |
|---|---|
| Cancer: | Melanoma |
| Drug Class: | PD-L1 inhibitor + CTLA4 inhibitor |
| Direction: | Sensitive |
Evidence:
Source:
Title:
913 / 15 - Defining melanoma patients unresponsive to single agent anti-PD-1 therapy but responsive to combination anti-PD-1 + anti-CTLA-4 therapy
Published date:
05/27/2020
Excerpt:
...the proportion of TCF7+ CD8 T cells was significantly higher at baseline (p=0.01) and in all tumor samples (p=0.007) in responders compared to non-responders. RNA differential gene expression analysis revealed higher expression of cancer testis antigens (CTAs) in responding patient tumors...The proportion of TCF7+ CD8 T cells and the presence of melanoma cancer testis antigens may be a predictive biomarker of response to combination immunotherapy in patients failing anti-PD-1 monotherapy.
